Media headlines about Opexa Therapeutics (NASDAQ:ACER) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Opexa Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.1817214874676 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Opexa Therapeutics (NASDAQ ACER) opened at $16.63 on Friday. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63.

Opexa Therapeutics (NASDAQ:ACER) last announced its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter.

Separately, ValuEngine upgraded Opexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd.

TRADEMARK VIOLATION NOTICE: “Opexa Therapeutics (ACER) Earns Daily News Impact Rating of 0.06” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with's FREE daily email newsletter.